Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

Journal of General Internal Medicine
Lisa Sanderson CoxRichard D Hurt

Abstract

This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking ...Continue Reading

References

Sep 26, 1990·JAMA : the Journal of the American Medical Association·A H GlassmanJ Johnson
May 20, 1988·JAMA : the Journal of the American Medical Association·A H GlassmanL S Covey
Oct 1, 1993·The American Journal of Psychiatry·L S CoveyJ Becker
Aug 26, 1998·Archives of General Psychiatry·S M HallE Triffleman
Apr 22, 1999·The British Journal of Psychiatry : the Journal of Mental Science·K E HayfordR D Hurt
Jan 8, 2000·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·J T HaysM C Fiore
Mar 4, 2000·The American Journal of Psychiatry·J Y TsohS M Hall
Nov 10, 2000·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·R NiauraM G Goldstein
Nov 22, 2000·JAMA : the Journal of the American Medical Association·K LasserD H Bor
Feb 22, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H S ThorsteinssonM Rapaport

❮ Previous
Next ❯

Citations

Apr 24, 2007·Neurotoxicity Research·Neil E Paterson, Athina Markou
Jan 21, 2010·Cancer Causes & Control : CCC·Robert A SchnollFrank Leone
Aug 22, 2002·Addictive Behaviors·Richard D HurtKenneth P Offord
Jul 23, 2005·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·E Paul WileytoCaryn Lerman
Jun 20, 2007·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Richard A BrownIvan W Miller
Oct 27, 2012·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Andrea H WeinbergerSherry A McKee
Aug 12, 2010·Oncology·Janine K CataldoJodi J Prochaska
Aug 15, 2006·Behavioral Medicine·Ludmila Cofta-WoerpelDavid W Wetter
Jul 10, 2004·Journal of General Internal Medicine·Wayne J Katon
Jun 10, 2011·American Journal of Public Health·Sharon M HallJulie A Robbins
Oct 3, 2006·Expert Review of Neurotherapeutics·Kevin F FoleyRichard E Kast
Aug 31, 2006·Expert Opinion on Emerging Drugs·Robert A Schnoll, Caryn Lerman
Sep 12, 2015·The American Journal on Addictions·Marya MorozovaTony P George
Jul 12, 2008·American Journal of Preventive Medicine·UNKNOWN Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff
Jul 25, 2008·Drug and Alcohol Dependence·Peter JatlowStephanie S O'Malley
Apr 28, 2009·Addiction·Sharon M HallJudith J Prochaska
May 17, 2006·International Journal of Clinical Practice·P Aveyard
Feb 25, 2006·Pulmonary Pharmacology & Therapeutics·I MitrouskaN M Siafakas
Dec 23, 2014·Journal of Substance Abuse Treatment·Arthur S HongJon O Ebbert
Feb 14, 2018·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Giulia A AldiFiammetta Cosci
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Amanda C FarleyPaul Aveyard
Jan 10, 2014·The Cochrane Database of Systematic Reviews·John R HughesTim Lancaster
Sep 15, 2018·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Allison J CarrollBrian Hitsman
Aug 22, 2013·The Cochrane Database of Systematic Reviews·Peter HajekTim Lancaster
Feb 14, 2019·The Cochrane Database of Systematic Reviews·Jonathan Livingstone-BanksPeter Hajek
Nov 7, 2019·The Cochrane Database of Systematic Reviews·Jonathan Livingstone-BanksPeter Hajek
Apr 23, 2020·The Cochrane Database of Systematic Reviews·Seth HowesNicola Lindson
Jul 22, 2015·Current Opinion in Cardiology·Judith J Prochaska, Neal L Benowitz
Aug 22, 2013·The Cochrane Database of Systematic Reviews·Regina M van der MeerPim Cuijpers
Mar 1, 2011·Irish Journal of Psychological Medicine·Sabina Feeney, Brian Hallahan
Oct 7, 2021·The Cochrane Database of Systematic Reviews·Jamie Hartmann-BoycePaul Aveyard

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.